JNJ

NYSE

JOHNSON & JOHNSON

Health Care, Pharmaceuticals

$259.24

close 7 Aug 2026

+49.14%

52-week change

$624.74B

market cap

$171.81

$274.90

52-week range

Valuation

Market cap$624.74B

P/E (TTM / 5y avg)30.11x21.77x

Forward P/E (FY2026 / FY2027)23.46x21.06x

PEG (TTM / fwd)1.682.07

P/S (TTM)6.38x

P/B7.35x

EV/EBITDA (TTM)19.31x

FCF yield (TTM)3.56%

Cash flow & dividend

FCF (TTM)$22.24B

FCF per share (TTM)$9.23

FCF margin (TTM)22.71%

Dividend yield (indicated / 5y avg)2.07%2.80%

Annualized dividend$5.36

Payout ratio (EPS / FCF)59.99%56.74%

Growth & quality

Revenue YoY, latest Q+6.60%

Diluted EPS YoY, latest Q-0.87%

Operating margin (TTM)—

Net margin (TTM)21.48%

ROE (latest FY)32.87%

Net debt / EBITDA (TTM)0.85

Interest coverage (TTM)—

Price

+47.09%+8.05%/yrover 5y

Weekly closes · split-adjusted

close 7 Aug 2026

Fundamentals

Fiscal years, last 10, CAGR chips on growth series, plus a dimmed trailing-twelve-month bar

Revenue

5Y CAGR +2.67%10Y CAGR +3%

Diluted EPS

5Y CAGR +14.89%10Y CAGR +7.25%

FCF per share

5Y CAGR +1.40%10Y CAGR +3.53%

Operating cash flow

5Y CAGR +0.83%10Y CAGR +2.29%

Free cash flow

5Y CAGR -0.49%10Y CAGR +2.03%

Dividends per share

5Y CAGR +5.36%10Y CAGR +5.77%

Payout ratio

FCF payout ratio

FCF margin

Return on equity

Shares outstanding

5Y CAGR -1.87%10Y CAGR -1.45%

Net debt / EBITDA

Earnings

Street estimates, not SEC filings

Next / Q3 FY26

Date13 Oct 2026

EPS estimate$3.08

Revenue estimate$25.57B

Last reported

Date—

EPS——

Revenue——